Consolidated Financial Results for the Six Months Ended September 30, 2026 (JPGAAP)

November 9, 2026

Name of listed company: Nissan Chemical Corporation
Stock Exchange: Tokyo
Code number: 4021
URL: https://www.nissanchem.co.jp/
Representative: YAGI Shinsuke, President
Inquiry to: NOMURA Hiroshi, Head of Finance and Accounting Department Tel. +81 3 4463 8401
Scheduled submission date of semi-annual securities report: November 10, 2026 Scheduled dividend payment date: December 7,2026
Supplemental information: Yes
Financial results meeting : Yes (For institutional investors and analysts)

(Amounts rounded down to the nearest million yen)

1. Consolidated Financial Results for the Six Months Ended September 30, 2026 (From April 1, 2026 to September 30, 2026)

(1) Consolidated Operating Results

(% indicates the rate of increase/decrease against the same period of the previous year)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended September 30, 2026	145,584	11.9	34,192	15.5	34,686	16.4	26,028	14.0
Six months ended September 30, 2025	130,094	10.1	29,598	4.4	29,788	6.6	22,827	11.2

(Note) Comprehensive income: Six months ended September 30, 2026 : 28,761 million yen ,10.9%
Six months ended September 30, 2025 : 25,943 million yen ,39.1%

	Basic earnings per share	Diluted net income per share
	Yen	Yen
Six months ended September 30, 2026	194.70	—
Six months ended September 30, 2025	168.45	—

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of September 30, 2026	353,594	265,147	73.8
As of March 31, 2026	355,078	259,051	71.9

(Reference) Shareholders' equity: As of September 30, 2026 : 260,911 million yen
As of March 31, 2026 : 255,264 million yen

2. Cash Dividends

	Cash dividends per share				
	First quarter	Second quarter	Third quarter	Year-end	Annual
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2026	—	70.00	—	132.00	202.00
Year ending March 31, 2027	—	78.00			
Year ending March 31, 2027 (Outlook)			—	142.00	220.00

(Note) Revision of the latest released dividend outlook: Yes
Please refer to "Notice Regarding Revision of Financial Results Outlook, Payment of Interim Dividend, and Revision of Annual Dividend Outlook" for details.

3. Outlook of Consolidated Financial Results for the Fiscal Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

(% indicates the rate of increase/decrease against the same period of the previous year)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Year ending March 31, 2027	311,100	11.3	72,400	13.9	72,100	9.4	53,300	7.2	399.93

(Note) Revision of the latest released outlook of financial results: Yes
Please refer to "Notice Regarding Revision of Financial Results Outlook, Payment of Interim Dividend, and Revision of Annual Dividend Outlook" for details.

4. Notes

(1) Changes in significant consolidated subsidiaries

(Changes in specified subsidiaries involving changes in scope of consolidation) : Yes

Newly Included: 1 company (Company name:Nissan Chemical Materials Research (Suzhou) Co., Ltd.)

(2) Application of special accounting treatment to preparation of quarterly financial statements : None

(3) Changes of accounting policies and accounting estimates, and restatement

1. Changes of accounting policies due to revisions of accounting standards : Yes
2. Changes of accounting policies other than the above : None
3. Changes in accounting estimates : None
4. Restatements : None

(Note)Please refer to [2. Consolidated Financial Statements (4) Notes to Consolidated Financial Statements (Changes in AccountingPolicies)] on page 11 for further details.

(4) Number of shares outstanding (common shares)

1. Number of shares outstanding (including treasury shares)

As of September 30, 2026 : 134,800,000 shares

As of March 31, 2026 : 134,800,000 shares

2. Number of treasury shares

As of September 30, 2026 : 1,401,767 shares

As of March 31, 2026 : 691,415 shares

3. Average number of shares outstanding

As of September 30, 2026 : 133,686,184 shares

As of September 30, 2025 : 135,511,720 shares

(Note) The Company has introduced “Board Benefit Trust (BBT)” based on the resolution of Board of Directors' meeting held on July 30, 2019.The shares held by the Trust are included in the number of treasury shares at the end of the period, and they are included in the number of treasury shares deducted in calculating the average number of shares outstanding over the period. The number of shares held by the Trust (included in treasury shares) at the end of the period was 395,600 shares.
In addition, the average number of shares held by the Trust during the period was 194,017 shares.
This is not included in the average number of shares outstanding.

* Presentation regarding implementation status of quarterly(Semi-annual) review procedures

The financial release is not subject to quarterly(Semi-annual) review.

* Explanations regarding appropriate use of business outlook and other special notes

The business outlook contained in this report is based on information available at the time of disclosure.
Actual operating results may differ materially from the outlook due to various factors.

For supplemental information, please refer to our website.
The transcript of financial results briefing will be released on our website as well.

Table of Contents for Attached Materials

1. Qualitative Information on Quarterly Results 2
(1) Business Performance 2
(2) Financial Position 4
(3) Outlook of Consolidated Financial Results and Other Forward-looking Information 5
(4) Basic Policy on Distribution of Earnings 5
2. Consolidated Financial Statements 6
(1) Consolidated Balance Sheets 6
(2) Consolidated Statements of Income / Consolidated Statements of Comprehensive Income 8
(3) Consolidated Statements of Cash Flows 10
(4) Notes to Consolidated Financial Statements 11
(Notes on Assumption of Going Concern) 11
(Notes on Significant Changes in Shareholders' Equity) 11
(Changes in Accounting Policies) 11
(Changes in presentation) 11
(Segment Information) 12
(Significant Subsequent Events) 13

1. Qualitative Information on Quarterly Results

(1) Business Performance

During the second quarter of the current fiscal year (April 1, 2026 to September 30, 2026), the global economy remained resilient and was supported by global demand driven by the technology cycle associated with the advancement and widespread adoption of artificial intelligence (AI). However, downside risks remained due to the prolonged situation in the Middle East and continuing trade friction. Under these circumstances, in the Performance Materials Segment, sales increased significantly, mainly due to strong sales of Semiconductor Materials. In the Agricultural Chemicals Segment, sales decreased due to lower sales of overseas markets. In the Chemicals Segment, sales of both Basic Chemicals and Fine Chemicals increased. In the Healthcare Segment, sales increased.

As a result, sales and each income during the period exceeded both the same period of the previous fiscal year and the outlook announced in May.

(Million yen, amount rounded down to the nearest million yen)

	2Q FY2025	2Q FY2026	Year-on-Year Change	2Q FY2026 (Outlook)	Change from Outlook
Sales	130,094	145,584	+15,489	131,500	+14,084
Operating income	29,598	34,192	+4,594	28,700	+5,492
Ordinary income	29,788	34,686	+4,898	29,600	+5,086
Net income attributable to owners of parent	22,827	26,028	+3,201	22,400	+3,628

Explanations by segments are as below.

The Performance Materials Segment

In Semiconductor Materials, sales of anti-reflective coating for semiconductors (ARC®*) and multi-layer process materials (OptiStack®*) increased significantly due to high customer utilization. In Display Materials, sales of "SUNEVER" (LCD alignment coating) decreased due to the impact of higher semiconductor memory prices. In Inorganic Materials, sales of "SNOWTEX" (for polishing electronic materials and hard coating), Organo / Monomer sol (various coatings and resin additives), and Oilfield materials (for enhancing oil recovery) increased.

As a result, sales of this segment were 67,040 million yen (an increase of 12,623 million yen from the same period of the previous fiscal year) and operating income was 20,862 million yen (an increase of 3,495 million yen). Compared to the outlook (Note), sales were above 6.8 billion yen and operating income was above 3.1 billion yen.

* ARC® and OptiStack® are registered trademarks of Brewer Science, Inc.

(Note) The outlook is described on page 40 of the FY2025 Presentation Materials (announced on May 15, 2026).

The Agricultural Chemicals Segment

Sales of Fluralaner (active ingredients for veterinary pharmaceuticals) decreased. In the Japanese domestic market, sales of "ROUNDUP" (non-selective foliar application herbicide) and "ALTAIR" (paddy rice herbicide) were firm. In the overseas market, sales of "GRACIA" (insecticide) were firm, while sales of "LEIMAY" (fungicide) decreased.

As a result, sales of this segment were 41,376 million yen (a decrease of 896 million yen) and operating income was 11,898 million yen (a decrease of 76 million yen). Compared to the outlook (Note), sales were above 2.2 billion yen and operating income was above 0.8 billion yen.

(Note) The outlook is described on page 40 of the FY2025 Presentation Materials (announced on May 15, 2026).

The Chemicals Segment

In Basic Chemicals, sales of high purity sulfuric acid (agent used for cleaning semiconductor) and nitric acid products (metal dissolution and surface treatment, etc.) increased. In Fine Chemicals, sales of "TEPIC" (powder coating agent for paint, sealants, etc.) and environmental related products (sterilizing and disinfecting agents for pools and septic tanks, etc.) increased.

As a result, sales of this segment were 20,600 million yen (an increase of 1,770 million yen) and operating loss was 210 million yen (an increase in loss of 112 million yen). Compared to the outlook (Note), sales were above 1.0 billion yen and operating income was below 0.5 billion yen.

(Note) The outlook is described on page 40 of the FY2025 Presentation Materials (announced on May 15, 2026).

The Healthcare Segment

Sales of "LIVALO®*" (anti-cholesterol drug) active ingredient increased in both the domestic and overseas markets. Sales of "Custom Chemicals" (solution proposal business and joint development business) remained flat compared to the previous fiscal year.

As a result, sales of this segment were 3,060 million yen (an increase of 228 million yen) and operating income was 856 million yen (an increase of 161 million yen). Compared to the outlook (Note), sales were above 0.6 billion yen and operating income was above 0.4 billion yen.

*LIVALO® is a registered trademark of Kowa Company, Ltd.

(Note) The outlook is described on page 40 of the FY2025 Presentation Materials (announced on May 15, 2026).

Trading

Sales of this segment were 75,222 million yen (an increase of 16,429 million yen) and operating income was 2,488 million yen (an increase of 533 million yen). Compared to the outlook (Note), sales were above 11.5 billion yen and operating income was above 0.9 billion yen.

(Note) The outlook is described on page 56 and 57 of the FY2025 Presentation Materials (announced on May 15, 2026).

Others

Sales of this segment were 20,658 million yen (an increase of 5,812 million yen) and operating income was 1,071 million yen (an increase of 282 million yen).

(2) Financial Position

(Position of Assets, Liabilities and Net Assets)

Total assets as of September 30, 2026 was 353,594 million yen (a decrease of 1,483 million yen from March 31, 2026). It is mainly due to the decrease notes and accounts receivable - trade, though cash and deposits increased.

Total liabilities as of September 30, 2026 was 88,447 million yen (a decrease of 7,579 million yen). It is mainly due to the decrease of short-term loans payable and commercial papers.

Net assets as of September 30, 2026 was 265,147 million yen (an increase of 6,095 million yen).

As a result of these factors, equity ratio was 73.8% (an increase of 1.9% from March 31, 2026).

(Position of Cash Flows)

Deducting income taxes paid from income before income taxes and non-controlling interests, depreciation and change in working capital, net cash provided by operating activities for the six months ended September 30, 2026 was 54,771 million yen (48,711 million yen for the same period of the previous year).

Mainly due to capital investment in factories, etc., net cash used in investing activities for the six months ended September 30, 2026 was 11,671 million yen (8,085 million yen for the same period of the previous year).

Due to the decrease in loans payable, payment for dividends and share repurchase, net cash used in financing activities for the six months ended September 30, 2026 was 37,640 million yen (35,041 million yen for the same period of the previous year).

Cash and cash equivalents at the end of this period increased 6,300 million yen from March 31, 2026 after adjusting for the 840 million yen of increase as an effect of exchange rate change. Moreover, after adding the 920 million yen increase in cash and cash equivalents from newly consolidated subsidiary, the balance stood at 42,950 million yen (34,274 million yen for the same period of the previous year).

(3) Outlook of Consolidated Financial Results and Other Forward-looking Information

Outlook for the year ending March 31, 2027 was revised as follows based on the cumulative second quarter and demand forecast. The exchange rate for the third quarter and beyond is assumed to be 152 yen to the U.S. dollar.

Revision of consolidated financial results' outlook for the year ending March 31, 2027 (April 1, 2026 to March 31, 2027)

(Billion yen)

	Previous outlook(A)	Revised outlook(B)	Change (B-A)	Rate of change (%)	(Reference) Results for the previous fiscal year
Sales	289.7	311.1	+21.4	+7.4%	279.6
Operating income	66.8	72.4	+5.6	+8.4%	63.6
Ordinary income	68.8	72.1	+3.3	+4.8%	65.9
Net income attributable to owners of parent	51.5	53.3	+1.8	+3.5%	49.7
Basic earnings per share	387.11 yen	399.93 yen	+12.82 yen	+3.3%	368.26 yen

Revision of consolidated sales and operating income outlook by segments for the year ending March 31, 2027

(Billion yen)

	Sales		Operating income	
	Previous	Revised	Previous	Revised
Performance Materials	126.1	136.8	38.6	41.6
Agricultural Chemicals	97.2	100.2	27.0	27.4
Chemicals	41.4	45.6	1.3	1.5
Healthcare	5.5	5.8	1.1	1.4
Trading	137.8	153.3	3.5	4.5
Others	37.5	39.7	1.7	1.9
Adjustment	(155.8)	(170.3)	(6.4)	(5.9)
Total	289.7	311.1	66.8	72.4

(4) Basic Policy on Distribution of Earnings

The Company's basic policy of profit allocation is returning to shareholders by improving company value through increasing revenue in the medium and long terms.

In medium-term business plan "Vista2027" Stage Ⅱ launched from April 2025, the company aims to realize dividend payout ratio to be 55% or more and total payout ratio to be 75% or more after FY2025.

2. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Million yen)

	As of March 31, 2026	As of September 30, 2026
Asset		
Current assets		
Cash and deposits	35,729	42,950
Notes and accounts receivable - trade, and contract assets	93,134	75,067
Electronically recorded monetary claims - operating	4,033	3,364
Merchandise and finished goods	56,991	61,358
Work in process	14	321
Raw materials and supplies	19,634	20,053
Accounts receivable - other	2,643	2,183
Short-term loans receivable	445	814
Other	9,399	8,565
Allowance for doubtful accounts	(73)	(82)
Total current assets	221,951	214,596
Non-current assets		
Property, plant and equipment		
Buildings and structures	92,180	95,280
Accumulated depreciation and impairment loss	(57,502)	(58,770)
Buildings and structures, net	34,677	36,509
Machinery, equipment and vehicles	182,744	191,551
Accumulated depreciation and impairment loss	(161,658)	(167,674)
Machinery, equipment and vehicles, net	21,086	23,877
Tools, furniture and fixtures	49,801	50,520
Accumulated depreciation and impairment loss	(43,510)	(44,380)
Tools, furniture and fixtures, net	6,290	6,140
Land	8,827	8,832
Leased assets	149	138
Accumulated depreciation	(25)	(32)
Leased assets, net	124	106
Construction in progress	5,961	6,987
Total property, plant and equipment	76,968	82,453
Intangible assets		
Software	3,544	3,427
Other	9,225	8,288
Total intangible assets	12,770	11,716
Investments and other assets		
Investment securities	32,477	34,402
Long-term loans receivable	117	111
Deferred tax assets	554	623
Net defined benefit asset	5,750	5,796
Other	4,540	3,945
Allowance for doubtful accounts	(52)	(52)
Total investments and other assets	43,387	44,826
Total non-current assets	133,126	138,997
Total assets	355,078	353,594

(Million yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	22,485	23,841
Electronically recorded obligations - operating	69	37
Short-term loans payable	19,682	2,471
Commercial papers	7,993	—
Current portion of long-term loans payable	382	327
Income taxes payable	7,899	7,875
Provision for bonuses	2,785	2,896
Other	16,980	21,849
Total current liabilities	78,279	59,298
Non-current liabilities		
Bonds payable	10,000	20,000
Long-term loans payable	388	1,334
Deferred tax liabilities	3,712	3,882
Provision for share-based remuneration for directors (and other officers)	276	328
Net defined benefit liability	642	813
Other	2,727	2,789
Total non-current liabilities	17,747	29,148
Total liabilities	96,026	88,447
Net assets		
Shareholders' equity		
Capital stock	18,942	18,942
Capital surplus	13,613	13,904
Retained earnings	209,641	218,297
Treasury shares	(3,424)	(9,178)
Total shareholders' equity	238,772	241,965
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	11,451	11,649
Foreign currency translation adjustment	3,097	5,483
Remeasurements of defined benefit plans	1,943	1,812
Total accumulated other comprehensive income	16,492	18,945
Non-controlling interests	3,786	4,236
Total net assets	259,051	265,147
Total liabilities and net assets	355,078	353,594

(2) Consolidated Statements of Income / Consolidated Statements of Comprehensive Income

- Consolidated Statements of Income

(Million yen)

	Six Months Ended September 30, 2025	Six Months Ended September 30, 2026
Net sales	130,094	145,584
Cost of sales	68,253	74,632
Gross profit	61,840	70,951
Selling, general and administrative expenses	32,242	36,758
Operating income	29,598	34,192
Non-operating income		
Interest income	84	114
Dividend income	1,086	1,113
Equity in earnings of affiliates	161	815
Other	447	452
Total non-operating income	1,779	2,496
Non-operating expenses		
Interest expenses	222	278
Loss on disposal of non-current assets	565	400
Bond issuance costs	0	53
Plant stop losses	127	48
Foreign exchange losses	447	1,076
Other	226	143
Total non- operating expenses	1,589	2,002
Ordinary income	29,788	34,686
Extraordinary income		
Total extraordinary income	—	—
Extraordinary losses		
Total extraordinary losses	—	—
Income before income taxes and non-controlling interests	29,788	34,686
Income taxes - current	6,191	8,163
Income taxes - deferred	432	121
Total income taxes	6,624	8,285
Net income	23,164	26,401
Net income attributable to non-controlling interests	336	373
Net income attributable to owners of parent	22,827	26,028

- Consolidated Statements of Comprehensive Income

(Million yen)

	Six Months Ended September 30, 2025	Six Months Ended September 30, 2026
Net income	23,164	26,401
Other comprehensive income		
Valuation difference on available-for-sale securities	1,540	192
Foreign currency translation adjustment	1,343	2,285
Remeasurements of defined benefit plans, net of tax	(105)	(130)
Share of other comprehensive income of entities accounted for using equity method	0	11
Total other comprehensive income	2,779	2,359
Comprehensive income	25,943	28,761
(Comprehensive income attributable to)		
Owners of parent	25,377	28,153
Non-controlling interests	566	607

(3) Consolidated Statements of Cash Flows

(Million yen)

	Six Months Ended September 30, 2025	Six Months Ended September 30, 2026
Cash flows from operating activities		
Income before income taxes and non-controlling interests	29,788	34,686
Depreciation	6,892	7,640
Amortization of goodwill	68	33
Interest and dividend income	(1,170)	(1,228)
Interest expenses	222	278
Loss (gain) on disposal of non-current assets	565	400
Decrease (increase) in notes and accounts receivable - trade	15,649	19,620
Decrease (increase) in inventories	829	(4,383)
Increase (decrease) in notes and accounts payable - trade	356	1,095
Other	3,190	2,855
Subtotal	56,392	61,000
Interest and dividend income received	2,058	2,287
Interest expenses paid	(219)	(212)
Income taxes paid	(9,519)	(8,304)
Net cash provided by (used in) operating activities	48,711	54,771
Cash flows from investing activities		
Purchase of investment securities	(115)	(1,212)
Purchase of shares of subsidiaries and associates	—	(190)
Purchase of property, plant and equipment	(8,477)	(8,972)
Payments for retirement of property, plant and equipment	(327)	(342)
Purchase of intangible assets	(605)	(440)
Net decrease (increase) in short-term loans receivable	1,671	(373)
Purchase of long-term prepaid expenses	(39)	(137)
Other	(192)	(1)
Net cash provided by (used in) investing activities	(8,085)	(11,671)
Cash flows from financing activities		
Net increase (decrease) in short-term loans payable	(8,776)	(17,171)
Net increase (decrease) in commercial papers	(4,997)	(7,993)
Proceeds from long-term borrowings	—	1,108
Repayments of long-term loans payable	(464)	(191)
Proceeds from issuance of bonds	—	10,000
Cash dividends paid	(14,187)	(17,719)
Dividends paid to non-controlling interests	(105)	(158)
Share repurchase	(6,499)	(7,549)
Proceeds from disposal of treasury shares	—	2,049
Other	(9)	(15)
Net cash provided by (used in) financing activities	(35,041)	(37,640)
Effect of exchange rate change on cash and cash equivalents	1,234	840
Net increase (decrease) in cash and cash equivalents	6,819	6,300
Cash and cash equivalents at beginning of period	27,454	35,729
Increase in cash and cash equivalents from newly consolidated subsidiary	—	920
Cash and cash equivalents at end of period	34,274	42,950

(4) Notes to Consolidated Financial Statements

(Notes on Assumption of Going Concern)

Not applicable.

(Notes on Significant Changes in Shareholders' Equity)

The Company made a stock payment of 7,600 shares to the eligible party on April 24, May 25, and July 24, 2026 based on the trust agreement of the Board Benefit Trust (BBT) resolved by the Board of Director's meeting on July 30, 2019. As a result, treasury shares decreased by 36 million yen during the second quarter of current consolidated fiscal year.

The Company repurchased 717,900 treasury shares based on the resolution of Board of Directors' meeting held on May 15, 2026. As a result, treasury shares increased by 5,499 million yen during the second quarter of current consolidated fiscal year.

Based on the resolution of the Board of Directors' meeting held on August 7, 2026, the Company disposed of 271,000 treasury shares on August 24, 2026 in connection with an additional contribution to the performance-linked stock compensation plan, the Board Benefit Trust (BBT). As a result, treasury shares decreased by 1,758 million yen and shares of the Company held by the trust increased by 2,049 million yen during the second quarter of current consolidated fiscal year. Shares of the Company held by the trust are included in treasury shares.

(Changes in Accounting Policies)

(Application of the Practical Guidelines on Accounting for Financial Instruments)

The Practical Guidelines on Accounting for Financial Instruments (Revised Transferred Guidance No. 9, March 11, 2025) have been applied from the beginning of the current fiscal year. Thus, unlisted shares that comprise the assets of partnerships and similar entities corresponding to venture capital funds are measured at fair value, and the Company's share of the resulting valuation differences is recorded in net assets.

In accordance with the transitional provisions of the Practical Guidelines, retrospective application was not made. The cumulative effect of this change in accounting policy has been reflected in the carrying amount of net assets at the beginning of the current fiscal year. As a result, the beginning balance of valuation difference on available-for-sale securities increased by 5 million yen.

(Changes in presentation)

(Consolidated balance sheet)

To enhance clarity, "Electronically recorded monetary claims - operating" and "Electronically recorded monetary obligations - operating", which were previously included in "Notes and accounts receivable - trade, and contract assets" and "Notes and accounts payable – trade", respectively, are presented separately from the current fiscal year. Accordingly, comparative figures for the previous fiscal year have been reclassified.

As a result, 97,167 million yen previously included in "Notes and accounts receivable - trade, and contract assets" as of the end of the previous fiscal year has been reclassified as 93,134 million yen of "Notes and accounts receivable - trade, and contract assets" and 4,033 million yen of "Electronically recorded monetary claims - operating" 22,555 million yen previously included in "Notes and accounts payable - trade" has been reclassified as 22,485 million yen of "Notes and accounts payable - trade" and 69 million yen of "Electronically recorded monetary obligations - operating".

(Segment Information)

1. Information Regarding Sales, Income (Loss) of Reportable Segments

1) For the Six Months Ended September 30, 2025 (From April 1, 2025 to September 30, 2025)

(Million yen)

	Performance Materials	Agricultural Chemicals	Chemicals	Healthcare	Trading	Others	Total	Adjustment (Note 2)	Consolidated Total
Net Sales									
Sales to outside customers (Note 1)	39,430	36,661	12,467	2,783	44,404	6,835	142,582	(12,488)	130,094
Intersegment Sales	14,986	5,611	6,362	48	14,388	8,010	49,407	(49,407)	—
Total Sales	54,417	42,273	18,830	2,831	58,792	14,845	191,990	(61,896)	130,094
Segment Income or Loss (Operating Income or Loss)	17,367	11,975	(97)	695	1,955	789	32,685	(3,086)	29,598

Notes:

1 Sales to outside customers in reportable segments are calculated on a gross basis, including sales that are agent transactions.
A reconciliation of gross sales to net sales as agent transactions is made in the Adjustments section.

2. Adjustments are as follows.

(1) (12,488) million yen adjustment in sales to outside customers includes (12,526) million yen in the elimination of agent transactions, and 37 million yen sales not attributable to any reporting segment.

(2) (3,086) million yen adjustment in segment income includes (130) million yen in intersegment eliminations, 37 million yen sales not attributable to any reporting segment, and (2,994) million yen corporate expenses not attributable to any reportable segment. The corporate expenses are mainly group administrative expenses which do not belong to any segment.

2) For the Six Months Ended September 30, 2026 (From April 1, 2026 to September 30, 2026)

(Million yen)

	Performance Materials	Agricultural Chemicals	Chemicals	Healthcare	Trading	Others	Total	Adjustment (Note 2)	Consolidated Total
Net Sales									
Sales to outside customers (Note 1)	42,330	35,230	13,899	3,055	57,705	7,346	159,567	(13,983)	145,584
Intersegment Sales	24,709	6,145	6,701	4	17,517	13,312	68,391	(68,391)	—
Total Sales	67,040	41,376	20,600	3,060	75,222	20,658	227,958	(82,374)	145,584
Segment Income or Loss (Operating Income or Loss)	20,862	11,898	(210)	856	2,488	1,071	36,968	(2,775)	34,192

Notes:

1 Sales to outside customers in reportable segments are calculated on a gross basis, including sales that are agent transactions.
A reconciliation of gross sales to net sales as agent transactions is made in the Adjustments section.

2. Adjustments are as follows.

(1) (13,983) million yen adjustment in sales to outside customers includes (14,045) million yen in the elimination of agent transactions, and 61 million yen sales not attributable to any reporting segment.

(2) (2,775) million yen adjustment in segment income includes 40 million yen in intersegment eliminations, 61 million yen sales not attributable to any reporting segment, and (2,877) million yen corporate expenses not attributable to any reportable segment. The corporate expenses are mainly group administrative expenses which do not belong to any segment.

(Significant Subsequent Events)

The Company established a subsidiary in China on September 1, 2026. Subsequently, on October 15, 2026, the Company made the first capital contribution of RMB 89 million (approximately JPY 2.1 billion) to the subsidiary.In addition, since the amount of capital of the subsidiary exceeds 10% of the amount of the Company's capital, the subsidiary qualifies as a specified subsidiary of the Company.

1. Purpose of the Establishment of the Company

The Company has established a subsidiary in Zhangjiagang City, Jiangsu Province, the People's Republic of China, with the aim of strengthening its supply framework in the growing Chinese semiconductor market.

In recent years, demand for semiconductors has continued to expand, driven by ongoing digitalization and other factors. At the same time, increasing customer demand for supply chain resilience has heightened the need for a more stable supply framework for semiconductor materials.The new company will manufacture and sell anti-reflective coating for semiconductors and multilayer materials. By strengthening its supply base in China and establishing a supply framework closer to customers, the Company aims to respond more promptly to changes in demand and further enhance customer service.

Through these initiatives, the Company seeks to achieve sustainable growth in its semiconductor materials business and enhance its corporate value.

2. Overview of the Subsidiary

(1) Company Name: Nissan Chemical Semiconductor materials Zhangjiagang Co., Ltd.
(2) Location: Zhangjiagang City, Jiangsu Province, People's Republic of China
(3) Representative: NAKADA Takakazu
(4) Business: Manufacture and sale of semiconductor materials
(5) Registered Capital: RMB 210 million (approximately JPY 5.0 billion) (scheduled)
(6) Date of Establishment: September 1, 2026
(7) Equity Ownership: 100% owned by the Company

3. Progress to Date

The establishment of the subsidiary was resolved at a meeting of the Board of Directors held on April 28, 2026. Subsequently, the Company entered into an investment agreement with Zhangjiagang City, Jiangsu Province, and the subsidiary was registered on September 1, 2026. Thereafter, the Company made the first capital contribution of RMB 89 million (approximately JPY 2.1 billion) on October 15, 2026.

4. Impact on Financial Results

The impact of this matter on the Company's financial results for the fiscal year ending March 31, 2027 is expected to be immaterial. The Company will promptly disclose any matters that require timely disclosure.